Temporary guidance for specialists is now available to support females of childbearing potential taking valproate during the COVID-19 pandemic, says the UK\'s MHRA.

Specifically, this temporary guidance has been published to support adherence to the Pregnancy Prevention Programme (PPP) requirements for \"*girls (of any age) and women of childbearing potential taking valproate during the pandemic, particularly patients who are shielding due to other health conditions*\", says the MHRA.

Valproate-containing medicines are referred to as \"black triangle medicines\" and all suspected ADRs linked with their use should be reported to the MHRA. \"*Children exposed to valproate in utero have a very high risk for congenital malformations (10% risk) and neurodevelopmental disorders (30−40% risk)*\", warned the agency.

Within the valproate PPP, the following points are noted, including:

patients receiving valproate who have experienced menarche must have, at least, an annual review with their prescribing specialist to reassess the need for valproate therapy, and also consider alternative treatment options.annual valproate therapy reviews should not be delayed due to the COVID-19 pandemic.no girl or woman of childbearing potential should stop taking valproate without first discussing it with their doctor.

Healthcare professionals, patients and caregivers are asked to submit all suspected ADR reports via the Yellow Card Scheme, and this guidance \"*will be updated once these temporary recommendations are no longer considered necessary*\", concluded the MHRA.
